A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Comparative Trial of Plerixafor (0.24 mg/kg) Plus G CSF (10 µg/kg) Versus G CSF (10 µg/kg) Plus Placebo to Mobilize and Collect ≥5 × 106 CD34+ Cells/kg in Non-Hodgkin's Lymphoma (NHL) Patients for Autologous Transplantation
收藏DataCite Commons2024-12-04 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00007727/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The study is to determine if NHL patients mobilized with G-CSF (10 µg/kg/day [GRAN® only])
plus 0.24 mg/kg/day of plerixafor are more likely to achieve a target number of ≥5 × 10^6
CD34+ cells/kg in 4 or fewer days of apheresis than NHL patients mobilized with G-CSF plus
placebo.
提供机构：
Vivli
创建时间：
2022-02-10
